Multiple stress signals activate mutant p53 in vivo

Cancer Research

Volumn 71, Issue 23, 2011, Pages 7168-7175

  Suh, Young Ah ^a   Post, Sean M ^a   Elizondo Fraire, Ana C ^a   Maccio, Daniela R ^a   Jackson, James G ^a   El Naggar, Adel K ^a   Van Pelt, Carolyn ^a   Terzian, Tamara ^b   Lozano, Guillermina ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; PROTEIN P53; REACTIVE OXYGEN METABOLITE;

ADENOCARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFECT; IN VIVO STUDY; LYMPHOMA; MOUSE; NONHUMAN; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA; SIGNAL TRANSDUCTION; STRESS; WILD TYPE;

ANIMALS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; DNA DAMAGE; DOXORUBICIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; GENES, RAS; MICE; MICE, INBRED C57BL; MUTATION; NEOPLASMS, EXPERIMENTAL; ONCOGENES; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-MDM2; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 82655181478     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-0459     Document Type: Article

References (41)

1. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009;9:701-13.
2. Appella E, Anderson CW. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 2001;268: 2764-72. (Pubitemid 32862957)
3. Freedman DA, Levine AJ. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol 1998;18:7288-93. (Pubitemid 28533048)
4. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-9. (Pubitemid 27220766)
5. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997;420:25-7. (Pubitemid 28037193)
6. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387:299-303. (Pubitemid 27220767)
7. Roth J, Dobbelstein M, Freedman DA, Shenk T, Levine AJ. Nucleocytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J 1998;17:554-64. (Pubitemid 28045495)
8. Dornan D, Wertz I, Shimizu H, Arnott D, Frantz GD, Dowd P, et al. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 2004;429:86-92. (Pubitemid 38620556)
9. Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S, et al. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 2003;112:779-91. (Pubitemid 36378882)
10. Chen D, Kon N, Li M, Zhang W, Qin J, Gu W. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 2005;121:1071-83. (Pubitemid 40884397)
11. Allton K, Jain AK, Herz HM, Tsai WW, Jung SY, Qin J, et al. Trim24 targets endogenous p53 for degradation. Proc Natl Acad Sci U S A 2009;106:11612-6.
12. Ho JW, Song JZ, Leung YK. Activation of p53 by specific agents in potential cancer therapy. Curr Med Chem Anticancer Agents 2005;5:131-5. (Pubitemid 40347986)
13. Soussi T, Lozano G. p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun 2005;331:834-42. (Pubitemid 40615514)
14. Temkin V, Karin M. From death receptor to reactive oxygen species and c-Jun N-terminal protein kinase: the receptor-interacting protein 1 odyssey. Immunol Rev 2007;220:8-21. (Pubitemid 350045563)
15. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2002;2:331-41. (Pubitemid 37328946)
16. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001;2:731-7. (Pubitemid 33679835)
17. de Stanchina E, McCurrach ME, Zindy F, Shieh SY, Ferbeyre G, Samuelson AV, et al. E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev 1998;12:2434-42. (Pubitemid 28371362)
18. Pomerantz J, Schreiber-Agus N, Liégeois NJ, Silverman A, Alland L, Chin L, et al. The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53. Cell 1998;92:713-23. (Pubitemid 28155311)
19. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 1998;12:2424-33. (Pubitemid 28371361)
20. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A 1998;95:8292-7. (Pubitemid 28326106)
21. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, et al. The alternative product from the human CDKN2A locus, p14 (ARF), participates in a regulatory feedback loop with p53 and MDM2. Embo J 1998;17:5001-14. (Pubitemid 28408466)
22. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998;92:725-34. (Pubitemid 28155312)
23. Korgaonkar C, Zhao L, Modestou M, Quelle DE. ARF function does not require p53 stabilization or Mdm2 relocalization. Mol Cell Biol 2002;22:196-206. (Pubitemid 33144268)
24. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004;119:861-72. (Pubitemid 40017691)
25. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004;119:847-60. (Pubitemid 40017690)
26. Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA, et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 2008;22:1337-44. (Pubitemid 351717524)
27. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001;410:1111-6. (Pubitemid 32391044)
28. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994;4:1-7.
29. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985;318:533-8. (Pubitemid 16173038)
30. Post SM, Quintas-Cardama A, Terzian T, Smith C, Eischen CM, Lozano G. p53-dependent senescence delays Emu-myc-induced B-cell lymphomagenesis. Oncogene 2010;29:1260-9.
31. Zheng S, El-Naggar AK, Kim ES, Kurie JM, Lozano G. A genetic mouse model for metastatic lung cancer with gender differences in survival. Oncogene 2007;26:6896-904. (Pubitemid 47609074)
32. Evans SC, Viswanathan M, Grier JD, Narayana M, El-Naggar AK, Lozano G. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene 2001;20:4041-9. (Pubitemid 32681609)
33. Qiang W, Cahill JM, Liu J, Kuang X, Liu N, Scofield VL, et al. Activation of transcription factor Nrf-2 and its downstream targets in response to moloney murine leukemia virus ts1-induced thiol depletion and oxidative stress in astrocytes. J Virol 2004;78:11926-38. (Pubitemid 39390778)
34. Post SM, Quintas-Cardama A, Pant V, Iwakuma T, Hamir A, Jackson JG, et al. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell 2010;18:220-30.
35. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 1999;13:2658-69. (Pubitemid 29508553)
36. Martindale JL, Holbrook NJ. Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol 2002;192:1-15. (Pubitemid 34587382)
37. Kemp CJ, Wheldon T, Balmain A. p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat Genet 1994;8:66-9.
38. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-11.
39. Li JM, Fan LM, George VT, Brooks G. Nox2 regulates endothelial cell cycle arrest and apoptosis via p21cip1 and p53. Free Radic Biol Med 2007;43:976-86. (Pubitemid 47241205)
40. Shackelford RE, Kaufmann WK, Paules RS. Oxidative stress and cell cycle checkpoint function. Free Radic Biol Med 2000;28:1387-404. (Pubitemid 30621482)
41. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE, Chumakov PM. The antioxidant function of the p53 tumor suppressor. Nat Med 2005;11:1306-13. (Pubitemid 41752911)